Research Analysts Set Expectations for IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Cantor Fitzgerald lifted their FY2025 earnings estimates for IDEAYA Biosciences in a report issued on Thursday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($1.30) for the year, up from their prior forecast of ($3.00). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Cantor Fitzgerald also issued estimates for IDEAYA Biosciences’ FY2026 earnings at ($3.04) EPS.

Other research analysts have also recently issued research reports about the company. Guggenheim began coverage on IDEAYA Biosciences in a research note on Thursday, September 18th. They issued a “buy” rating and a $50.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $62.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. Barclays assumed coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They issued an “overweight” rating and a $40.00 target price for the company. Royal Bank Of Canada lifted their price target on IDEAYA Biosciences from $38.00 to $41.00 and gave the company an “outperform” rating in a research report on Tuesday, October 21st. Finally, The Goldman Sachs Group upped their price objective on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Tuesday, October 21st. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.50.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $32.14 on Monday. The company has a market capitalization of $2.82 billion, a PE ratio of -17.28 and a beta of 0.14. IDEAYA Biosciences has a 52-week low of $13.45 and a 52-week high of $33.64. The business’s fifty day moving average is $28.11 and its 200 day moving average is $24.21.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to analysts’ expectations of $59.98 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IDYA. CWM LLC grew its holdings in shares of IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after purchasing an additional 1,814 shares during the last quarter. Signaturefd LLC boosted its position in shares of IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after purchasing an additional 2,271 shares during the period. Assetmark Inc. grew its stake in IDEAYA Biosciences by 9.9% during the 1st quarter. Assetmark Inc. now owns 49,750 shares of the company’s stock worth $815,000 after buying an additional 4,481 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company’s stock worth $349,000 after buying an additional 1,214 shares during the last quarter. Finally, Fiera Capital Corp increased its position in IDEAYA Biosciences by 2.1% during the first quarter. Fiera Capital Corp now owns 1,209,865 shares of the company’s stock worth $19,818,000 after buying an additional 25,398 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.